全文获取类型
收费全文 | 270907篇 |
免费 | 14042篇 |
国内免费 | 588篇 |
专业分类
耳鼻咽喉 | 3475篇 |
儿科学 | 8440篇 |
妇产科学 | 5796篇 |
基础医学 | 38890篇 |
口腔科学 | 6443篇 |
临床医学 | 21954篇 |
内科学 | 58711篇 |
皮肤病学 | 7116篇 |
神经病学 | 24100篇 |
特种医学 | 8771篇 |
外国民族医学 | 105篇 |
外科学 | 34402篇 |
综合类 | 1541篇 |
一般理论 | 76篇 |
预防医学 | 23948篇 |
眼科学 | 5526篇 |
药学 | 18820篇 |
4篇 | |
中国医学 | 909篇 |
肿瘤学 | 16510篇 |
出版年
2023年 | 1419篇 |
2022年 | 1044篇 |
2021年 | 4246篇 |
2020年 | 2621篇 |
2019年 | 4630篇 |
2018年 | 8304篇 |
2017年 | 5590篇 |
2016年 | 5648篇 |
2015年 | 6375篇 |
2014年 | 6989篇 |
2013年 | 10866篇 |
2012年 | 18111篇 |
2011年 | 18074篇 |
2010年 | 9399篇 |
2009年 | 7292篇 |
2008年 | 15592篇 |
2007年 | 16755篇 |
2006年 | 15518篇 |
2005年 | 15342篇 |
2004年 | 14378篇 |
2003年 | 13222篇 |
2002年 | 12521篇 |
2001年 | 7012篇 |
2000年 | 6938篇 |
1999年 | 6258篇 |
1998年 | 1290篇 |
1997年 | 1061篇 |
1996年 | 992篇 |
1995年 | 972篇 |
1992年 | 3630篇 |
1991年 | 3259篇 |
1990年 | 3097篇 |
1989年 | 2833篇 |
1988年 | 2671篇 |
1987年 | 2442篇 |
1986年 | 2345篇 |
1985年 | 2108篇 |
1984年 | 1625篇 |
1983年 | 1355篇 |
1979年 | 1348篇 |
1978年 | 958篇 |
1977年 | 913篇 |
1975年 | 895篇 |
1974年 | 1105篇 |
1973年 | 1113篇 |
1972年 | 1017篇 |
1971年 | 1019篇 |
1970年 | 959篇 |
1969年 | 992篇 |
1968年 | 867篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
2.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献
3.
4.
Andreas Lundin Martin Annborn Ola Borgquist Joachim Düring Johan Undén Christian Rylander 《Acta anaesthesiologica Scandinavica》2023,67(5):655-662
Patients admitted to intensive care after cardiac arrest are at risk of circulatory shock and early mortality due to cardiovascular failure. The aim of this study was to evaluate the ability of the veno-arterial pCO2 difference (∆pCO2; central venous CO2 – arterial CO2) and lactate to predict early mortality in postcardiac arrest patients. This was a pre-planned prospective observational sub-study of the target temperature management 2 trial. The sub-study patients were included at five Swedish sites. Repeated measurements of ∆pCO2 and lactate were conducted at 4, 8, 12, 16, 24, 48, and 72 h after randomization. We assessed the association between each marker and 96-h mortality and their prognostic value for 96-h mortality. One hundred sixty-three patients were included in the analysis. Mortality at 96 h was 17%. During the initial 24 h, there was no difference in ∆pCO2 levels between 96-h survivors and non-survivors. ∆pCO2 measured at 4 h was associated with an increased risk of death within 96 h (adjusted odds ratio: 1.15; 95% confidence interval [CI]: 1.02–1.29; p = .018). Lactate levels were associated with poor outcome over multiple measurements. The area under the receiving operating curve to predict death within 96 h was 0.59 (95% CI: 0.48–0.74) and 0.82 (95% CI: 0.72–0.92) for ∆pCO2 and lactate, respectively. Our results do not support the use of ∆pCO2 to identify patients with early mortality in the postresuscitation phase. In contrast, non-survivors demonstrated higher lactate levels in the initial phase and lactate identified patients with early mortality with moderate accuracy. 相似文献
5.
Tengzhi Liu Kathrine Røe Redalen Morten Karlsen 《Journal of labelled compounds & radiopharmaceuticals》2022,65(7):191-202
Cyclotron-produced copper-64 radioisotope tracers offer the possibility to perform both diagnostic investigation by positron emission tomography (PET) and radiotherapy by a theranostic approach with bifunctional chelators. The versatile chemical properties of copper add to the importance of this isotope in medicinal investigation. [64Cu][Cu (ATSM)] has shown to be a viable candidate for imaging of tumor hypoxia; a critical tumor microenvironment characteristic that typically signifies tumor progression and resistance to chemo-radiotherapy. Various production and radiosynthesis methods of [64Cu][Cu (ATSM)] exist in labs, but usually involved non-standardized equipment with varying production qualities and may not be easily implemented in wider hospital settings. [64Cu][Cu (ATSM)] was synthesized on a modified GE TRACERlab FXN automated synthesis module. End-of-synthesis (EOS) molar activity of [64Cu][Cu (ATSM)] was 2.2–5.5 Ci/μmol (HPLC), 2.2–2.6 Ci/μmol (ATSM-titration), and 3.0–4.4 Ci/μmol (ICP-MS). Radiochemical purity was determined to be >99% based on radio-HPLC. The final product maintained radiochemical purity after 20 h. We demonstrated a simple and feasible process development and quality control protocols for automated cyclotron production and synthesis of [64Cu][Cu (ATSM)] based on commercially distributed standardized synthesis modules suitable for PET imaging and theranostic studies. 相似文献
6.
7.
8.
9.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
10.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献